Literature DB >> 18668433

Human ABC transporters ABCG2 (BCRP) and ABCG4.

S Koshiba1, R An, H Saito, K Wakabayashi, A Tamura, T Ishikawa.   

Abstract

1. The human ABC transporter ABCG2 is regarded as a member of the phase III system for xenobiotic metabolism, and it has been suggested that this efflux pump is responsible for protecting the body from toxic xenobiotics and for removing metabolites. 2. This review paper will address the new aspects of ABCG2 in terms of post-translational modifications (i.e., disulfide bond formation, ubiquitination, and endoplasmic reticulum-associated degradation) of ABCG2 protein, high-speed screening, and quantitative structure-activity relationship (QSAR) analysis to evaluate ABCG2-drug interactions, and genetic polymorphisms potentially associated with photosensitivity. 3. In addition, new aspects of human ABCG4 and mouse Abcg4 are presented with respect to their molecular properties and potential physiological roles. Considering a high sequence similarity between ABCG1 and ABCG4, both Abcg4 and ABCG4 may be involved in the transport of cholesterol from neurons and astrocytes. Furthermore, high expression of the mouse Abcg4 protein in the testis implicates its involvement in transport of certain sex hormones.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18668433     DOI: 10.1080/00498250801986944

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  14 in total

Review 1.  ABCG transporters and disease.

Authors:  Owen M Woodward; Anna Köttgen; Michael Köttgen
Journal:  FEBS J       Date:  2011-06-13       Impact factor: 5.542

Review 2.  Blood-brain barrier structure and function and the challenges for CNS drug delivery.

Authors:  N Joan Abbott
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

3.  In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.

Authors:  Md Tozammel Hoque; Arpit Shah; Vijay More; David S Miller; Reina Bendayan
Journal:  J Neurochem       Date:  2015-11-13       Impact factor: 5.372

Review 4.  The blood-testis barrier and its implications for male contraception.

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Pharmacol Rev       Date:  2011-10-28       Impact factor: 25.468

5.  Direct evidence of abca1-mediated efflux of cholesterol at the mouse blood-brain barrier.

Authors:  Tuan Minh Do; Mélissa Ouellet; Frédéric Calon; Giovanna Chimini; Hélène Chacun; Robert Farinotti; Fanchon Bourasset
Journal:  Mol Cell Biochem       Date:  2011-06-10       Impact factor: 3.396

Review 6.  Drug transporters, the blood-testis barrier, and spermatogenesis.

Authors:  Linlin Su; Dolores D Mruk; C Yan Cheng
Journal:  J Endocrinol       Date:  2010-12-06       Impact factor: 4.286

7.  Role of breast cancer resistance protein in the adaptive response to cholestasis.

Authors:  Albert Mennone; Carol J Soroka; Kathy M Harry; James L Boyer
Journal:  Drug Metab Dispos       Date:  2010-07-02       Impact factor: 3.922

8.  In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.

Authors:  Sophie Hodin; Thierry Basset; Elodie Jacqueroux; Olivier Delezay; Anthony Clotagatide; Nathalie Perek; Patrick Mismetti; Xavier Delavenne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

Review 9.  Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.

Authors:  Lauren E Tebay; Holly Robertson; Stephen T Durant; Steven R Vitale; Trevor M Penning; Albena T Dinkova-Kostova; John D Hayes
Journal:  Free Radic Biol Med       Date:  2015-06-27       Impact factor: 7.376

10.  ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells.

Authors:  Lijun Huang; Qiang Lu; Yong Han; Zhe Li; Zhipei Zhang; Xiaofei Li
Journal:  Diagn Pathol       Date:  2012-12-17       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.